The largest database of trusted experimental protocols

21 protocols using kinetic microplate reader

1

Microtiter Dish Biofilm Disruption Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
The microtiter dish biofilm formation assay24 was utilized to assess the ability of the thiazole compounds to disrupt an adherent staphylococcal biofilm, similar to what has been described elsewhere25 (link). S. epidermidis ATCC 35984 was transferred to tryptic soy broth and incubated at 37°C for 24 h before being diluted 1:200 in tryptic soy broth + 1% glucose. This solution was transferred to each well of a 96-well microtiter plate and incubated at 37°C for 24 h to permit biofilm formation on the well surface. Bacteria were removed and wells were washed twice with PBS. Compounds 1, 2, or vancomycin were added (in triplicate) to wells and serially diluted. The microtiter plate was then incubated at 37°C for 24 h. The plate was washed twice by submerging in deionized water. 0.1% (w/v) crystal violet was added to each well and allowed to stain the biofilm for 20 min before addition of 95% ethanol to decolorize. Using a kinetic microplate reader (Molecular Devices, Sunnyvale, CA, USA), the optical density of each well at 595 nm was measured. Percent biofilm mass reduction was calculated for each treatment regimen as compared to the control (wells receiving no treatment).
+ Open protocol
+ Expand
2

Glucose Uptake Measurement Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Glucose influx was measured using a 2-Deoxyglucose Uptake Measurement Kit (COSMO BIO Co. Ltd., Tokyo Japan) according to the manufacturer’s instructions. In brief, cells were lysed and proteins were incubated with the reagents provided. Samples were transferred to 96-well microplates, and glucose influx was read at 450 nm in a kinetic microplate reader (Molecular Devices Japan). Control reactions were carried out with no protein and/or no substrate.
+ Open protocol
+ Expand
3

Compound 35 Cytotoxicity Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Compound 35 was evaluated (at concentrations ranging from 16 to 128 μM) against a human keratinocyte (HaCaT) cell line (AddexBio, San Diego, CA, USA) to determine the potential toxic effect to mammalian skin cells in vitro, as described in a previous report [23 (link)]. In brief, keratinocytes were cultured in DMEM supplemented with 10% FBS at 37 °C with CO2 (5%). Control cells received DMSO alone at a concentration equal to that in compound-treated cell samples. Cells were incubated with compound 35 (using triplicate samples) in a 96-well plate at 37 °C with CO2 (5%) for 24 hours. The assay reagent MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Promega, Madison, WI, USA) was subsequently added and the plate was incubated for four hours. Absorbance readings (at OD490) were taken using a kinetic microplate reader (Molecular Devices, Sunnyvale, CA, USA). The quantity of viable cells after treatment with compound 35 was expressed as a percentage of the viability of DMSO-treated control cells (average of triplicate wells ± standard deviation). The toxicity data was analyzed via a one-way ANOVA, with post hoc Dunnet’s multiple comparisons test (P < 0.05), utilizing GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA).
+ Open protocol
+ Expand
4

In vitro Mammalian Skin Cell Toxicity

Check if the same lab product or an alternative is used in the 5 most similar protocols
Compounds 7, 18, and 19 were assayed (at concentrations of 16, 32, 64, and 128 µM) against a human keratinocyte (HaCaT) cell line (AddexBio, San Diego, CA, USA) to determine the potential toxic effect to mammalian skin cells in vitro, as previously described.44 (link)–48 (link) In brief, cells were cultured in DMEM supplemented with 10% FBS at 37 °C with CO2 (5%). Control cells received DMSO alone at a concentration equal to that in drug-treated cell samples. The cells were incubated with the compounds (in triplicate) in a 96-well plate at 37 °C with CO2 (5%) for 24 hours. The assay reagent MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Promega, Madison, WI, USA) was subsequently added and the plate was incubated for four hours. Absorbance readings (at OD490) were taken using a kinetic microplate reader (Molecular Devices, Sunnyvale, CA, USA). The quantity of viable cells after treatment with each compound was expressed as a percentage of the viability of DMSO-treated control cells (average of triplicate wells ± standard deviation). The toxicity data was analyzed via a one-way ANOVA, with post hoc Dunnet’s multiple comparisons test (P < 0.05), utilizing GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA).
+ Open protocol
+ Expand
5

Cytotoxicity Screening of Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols
Compounds 15 were assayed (at concentrations of 5 μg/mL, 10 μg/mL, 20 μg/mL, and 40 μg/mL) against a human keratinocyte (HaCaT) cell line (Catalogue Number: T0020001, AddexBio, San Diego, CA, USA) to determine the potential toxic effect to mammalian skin cells in vitro as described before [18 (link)]. Briefly, cells were cultured in DMEM supplemented with 10% FBS at 37°C with CO2 (5%). Control cells received DMSO alone at a concentration equal to that in drug-treated cell samples. The cells were incubated with the compounds (in triplicate) in a 96-well plate at 37°C with CO2 (5%) for two hours prior to addition of the assay reagent MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Promega, Madison, WI, USA). Absorbance readings (at OD490) were taken using a kinetic microplate reader (Molecular Devices, Sunnyvale, CA, USA). The quantity of viable cells after treatment with each compound was expressed as a percentage of the viability of DMSO-treated control cells (average of triplicate wells ± standard deviation). The toxicity data was analyzed via a one-way ANOVA, with post hoc Dunnet’s multiple comparisons test (P < 0.05), utilizing GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA).
+ Open protocol
+ Expand
6

Cytotoxicity Evaluation of Phenylthiazole Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols
Phenylthiazole compounds were assayed (at concentrations of 8, 16, and 32) against a human colorectal adenocarcinoma (Caco-2) cell line to determine the potential toxic effect to mammalian cells in vitro. Briefly, cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), non-essential amino acids (1X), penicillin-streptomycin at 37 °C with 5% CO2. Compounds were added and serially diluted. Control cells received DMSO (the solvent of the compounds) alone at a concentration equal to that in compound-treated wells to determine the baseline measure of the cytotoxic impact of the compounds. The cells were incubated with the compounds (in triplicate) in a 96-well plate at 37 °C with 5% CO2 for 24 hours. The assay reagent MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (Promega, Madison, WI, USA) was subsequently added and the plate was incubated for four hours. Absorbance readings (at OD490) were recorded using a kinetic microplate reader (Molecular Devices, Sunnyvale, CA, USA). The quantity of viable cells after treatment with each compound was expressed as a percentage of the viability of DMSO-treated control cells (average of triplicate wells ± standard deviation).
+ Open protocol
+ Expand
7

Measurement of Myofibrillar ATPase Activity

Check if the same lab product or an alternative is used in the 5 most similar protocols
Myofibrillar ATPase activity was determined by measuring inorganic phosphate release40 (link). Myofibrillar proteins were isolated and purified, as previously reported41 (link),42 (link), and suspended in a F60 buffer with 500 mM NaCl. These proteins were extracted from week 1 post-MI and sham rat heart samples, as well as heart samples from cMyBP-C transgenic mice (NTG, AAA, and DDD). Protein was then determined by Coomassie blue staining (Bio-Rad Laboratories, Hercules, CA) of SDS-PAGE gels (Supplementary Fig. S10). The reaction mixture contained 0.25–0.5 mg/mL myofibrillar proteins, 15 mM Tris–HCl, 10 mM KCl, 2 mM MgCl2, 0.5 mM EGTA, and 5 mM ATP (pH 7.0). Assays were performed in a 96-well microtiter plate at pCa2+ concentrations (pCa) from 8.0 to 2.0 at 37 °C. The 120-µL reaction mixture was incubated at 37 °C for 15 min and centrifuged at 1500 rpm for 3 min. Each 30 µL of supernatant was transferred into a new 96-well microtiter plate and mixed with 170 µL distilled water (dH2O). A 30 µL detection reagent (Phosphate Assay Kit, Abcam) was added to create a reaction to develop color after which the production of inorganic phosphate was determined calorimetrically at 625 nm using a kinetic microplate reader (Molecular Devices). Calcium–stimulated ATPase activity was calculated by subtracting the activity at pCa 2.0 from the activity at pCa 8.0.
+ Open protocol
+ Expand
8

Cytotoxicity Evaluation of Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols
Compounds were assayed (at concentrations of 32, 64, 128, and 256 μM) against a human colorectal (HRT-18) cell line to determine the potential toxic effect to mammalian cells in vitro. Briefly, cells were cultured in RPMI-1640 medium supplemented with 10% fetal horse serum at 37 °C with CO2 (5%). Control cells received DMSO alone at a concentration equal to that in drug-treated cell samples. The cells were incubated with the compounds (in triplicate) in a 96-well plate at 37 °C with CO2 (5%) for two hours. The assay reagent MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Promega, Madison, WI, USA) was subsequently added and the plate was incubated for four hours. Absorbance readings (at OD490) were taken using a kinetic microplate reader (Molecular Devices, Sunnyvale, CA, USA). The quantity of viable cells after treatment with each compound was expressed as a percentage of the viability of DMSO-treated control cells (average of triplicate wells ± standard deviation). The toxicity data was analyzed via a two-way ANOVA, with post hoc Dunnet's multiple comparisons test (P < 0.05), utilizing GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA).
+ Open protocol
+ Expand
9

Cytotoxicity Evaluation of Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols
Compounds 1, 5, 22bd and 25 were assayed at concentrations of 5 μg/mL, 10 μg/mL, 20 μg/mL, and 40 μg/mL against a human embryonic kidney (HEK293) cell line to determine the potential toxic effect to mammalian cells in vitro. Cells were cultured in Dulbeco’s modified Eagle’s medium (Sigma-Aldrich, St. Louis, MO, USA) with 10% fetal bovine serum (USA Scientific, Inc.) at 37 °C with 5% CO2. Controls received DMSO alone at a concentration equal to that in drug-treated cell samples. The cells were incubated with the compounds in a 96-well plate at 37 °C and 5% CO2 for 2 hours prior to addition of the assay reagent MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Promega, Madison, WI, USA). Absorbance readings (at OD490) were taken using a kinetic microplate reader (Molecular Devices, Sunnyvale, CA, USA). The quantity of viable cells after treatment with each compound was expressed as a percentage of the viability of DMSO-treated control cells.
+ Open protocol
+ Expand
10

IFN-α and CXCL10 ELISA Quantification

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human IFN-α and CXCL10 ELISAs were purchased from PBL Assay Science (#41 100–2), R&D Systems (#SIP100), and Thermo Fisher (#KAC2361). Plates were read at 450 nm (with wavelength correction by subtracting readings at 540 nm) with a Molecular Devices Kinetic microplate reader and analyzed with SOFTmax computer software (Molecular Devices, Sunnyvale, California, USA).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!